Arbutus Biopharma Corporation ABUS
Set alert
4.00 USD -0.21 -4.99%
At close
4.04 +0.04 +1.06%
Pre-market · Nov 3, 7:45 AM ET
3.99 Day range 4.29
3.50 52-week range 5.45
- YTD
- -16.84%
- 1 year
- -15.43%
- Open
- 4.22
- Prev close
- 4.21
- Mkt cap
- 613.10M
- Vol
- 2.65M
- Avg vol
- 4.92M
- EPS
- 0.79
- P/E
- 5.06
- Div yield
- 0.00%
More statistics
- Low
- 3.99
- High
- 4.29
- Forward P/E
- -30.67
- Beta
- 0.62
- Short ratio
- 5.03
- Inst. own
- 72.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 4.79
- 200-d avg
- 4.52
- 1y target
- 5.46
15m chart
Built from the cached five-day intraday bars.
Signals (26)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:40 PM | 16 hours ago |
| RSI: Oversold | Nov 2, 3:40 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 1:10 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 11:10 AM | 21 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 21 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 21 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 22 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 22 hours ago |
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:55 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:40 AM | 4 days ago |
Newest 20 of 26.
Financial health
Altman Z-Score
28.57 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 4
- P/E 4
- P/B 2
Valuation
P/E -28.3×
FY 2016 5y median -5.7× FY 2025
P/S 65.4×
FY 2016 5y median 37.6× FY 2025
P/B 12.0×
FY 2016 5y median 3.9× FY 2025
P/FCF -23.3×
FY 2016 5y median -9.3× FY 2025
EV/EBITDA -27.5×
FY 2016 5y median -5.6× FY 2025
EV/Sales 64.5×
FY 2016 5y median 29.4× FY 2025
FCF Yield -4.3%
FY 2016 5y median -10.7% FY 2025
Profitability
Gross Margin 97.4%
FY 2016 5y median 100.0% FY 2025
Operating Margin -192.1%
FY 2016 5y median -430.5% FY 2025
Net Margin -237.9%
FY 2016 5y median -401.6% FY 2025
ROE -43.7%
FY 2016 5y median -50.8% FY 2025
ROIC -30.3%
FY 2016 5y median -40.2% FY 2025
ROA -35.4%
FY 2016 5y median -37.3% FY 2025
Growth (YoY)
Revenue 128.2%
FY 2016 FY 2025
Operating Income 64.6%
FY 2016 FY 2025
EPS (diluted) 55.3%
FY 2016 FY 2025
Free Cash Flow 39.1%
FY 2016 FY 2025
Financial Health
Current Ratio 15.7×
FY 2016 5y median 8.2× FY 2025
Quick Ratio 15.7×
FY 2016 5y median 8.2× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 0.4×
FY 2016 5y median 0.4× FY 2025
Interest Coverage -279×
FY 2016 5y median -170× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
